Is C-Peptide Replacement the Missing Link for Successful Treatment of Neurological Complications in Type 1 Diabetes?

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|9|1|37-46

ISSN： 1389-4501

Source： Current Drug Targets, Vol.9, Iss.1, 2008-01, pp. : 37-46

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of Type 2 diabetes mellitus based on glucagon-like peptide-1

By Holst J.J.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 9, 1999-09 ,pp. : 1409-1415

Informa Healthcare

Access to resources Recommend Favorite

Pharmacogenetics of Glucagon-like Peptide-1 Agonists for the Treatment of Type 2 Diabetes Mellitus

By  

Current Clinical Pharmacology, Vol. 12, Iss. 4, 2018-04 ,pp. : 202-209

Bentham Science Publishers

Access to resources Recommend Favorite

C-peptide and diabetic neuropathy

By Sima Anders AF  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 9, 2003-09 ,pp. : 1471-1488

Informa Healthcare

Access to resources Recommend Favorite

Hospitalisation, complications, raise treatment cost of type 2 diabetes

By  

Inpharma, Vol. 1, Iss. 1539, 2006-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Developments of Glucagon Like Peptide-1 (GLP-1) and Long-acting Analogs in Clinical and Preclinical Studies for Treatment of Type 2 Diabetes

By  

Current Pharmaceutical Biotechnology, Vol. 14, Iss. 9, 2013-10 ,pp. : 835-841

Bentham Science Publishers

Access to resources Recommend Favorite